Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials

Cold Spring Harbor Protocols

Volumn 2013, Issue 11, 2013, Pages 1006-1011

  Abate Shen, Cory ^a   Pandolfi, Pier Paolo ^b  

^a NewYork Presbyterian Hospital   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; CANCER MODEL; CANCER RESEARCH; DRUG SCREENING; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; IMAGING; MOUSE; NONHUMAN; PATHOLOGY; PHARMACODYNAMICS; PHENOTYPE; STUDY DESIGN; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; NEOPLASM; PATHOPHYSIOLOGY; TRANSGENIC ANIMAL;

ANTINEOPLASTIC AGENT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS;

EID: 84887054932     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top078774     Document Type: Article

References (10)

1. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. 2009. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552.
2. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. 2003. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238.
3. Hanahan D. 1984. Tumour development: Oncogenes in transgenic mice. Nature 312: 503-504.
4. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
5. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. 2011. The APL paradigm and the "co-clinical trial" project. Cancer Discov 1: 108-116.
6. Shen MM, Abate-Shen C. 2010. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 24: 1967-2000.
7. Singh M, Murriel CL, Johnson L. 2012. Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes. Cancer Res 72: 2695-2700.
8. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55.
9. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu Y-P, Price SM, Abate-Shen C, Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
10. Young NP, Crowley D, Jacks T. 2011. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 71: 4040-4047.